ImmVirX reports on operations for FY26
Targeted RNA immunotherapy platform advances toward Phase 2 IMPACT-CRC study, with IVX055 broadening the MAPK-targeted pipeline Melbourne, Australia 28 September 2026 – ImmVirX Pty Limited, a life sciences company developing next-generation, receptor-targeted oncolytic RNA immunotherapies, is pleased to provide a summary of its operations and financial results for the financial year ended 30 June […]